Scrip
US FTC against 12-14 years of exclusivity for innovator biologics
12 June 2009
Nancy Faigen
Please Login to read the full article.
12 June 2009
Nancy Faigen
A new report by the US Federal Trade Commission has concluded that a 12-to-14 year regulatory exclusivity period for pioneer biologics is unnecessary to sustain innovation by firms.
It is also too long to promote innovation, the report,
Emerging Healthcare Issues: Follow-on...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
